ARACELIS SILVA: Open Payments
NPI 1366841884 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,661 in 69 payments from 15 companies in 2025. Trend: 2023 $1,067 · 2024 $1,499 · 2025 $1,661
Food & beverage: $1,642Education: $19
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 24 | $383 |
| ABBVIE INC. | 13 | $300 |
| GlaxoSmithKline, LLC. | 6 | $194 |
| UCB, Inc. | 4 | $176 |
| Janssen Scientific Affairs, LLC | 1 | $141 |
| PFIZER INC. | 4 | $119 |
| Novartis Pharmaceuticals Corporation | 4 | $83 |
| AstraZeneca Pharmaceuticals LP | 3 | $62 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| Janssen Biotech, Inc. | 3 | $41 |
Products named: BENLYSTA, KRYSTEXXA, TREMFYA, RINVOQ, Bimzelx, XELJANZ, SKYRIZI, TAVNEOS.
Industry payments across TX — which companies pay providers there.
